

APPENDIX B
CLEAN COPY OF AMENDED CLAIMS

Claim 19. A method for radiosensitizing cancer cells, comprising the step of
delivering to said cancer cells an effective dose of an expressible nucleic acid encoding a
dominant negative mutant epidermal growth factor.

Claim 20. The method of claim 19, wherein said dominant negative mutant epidermal growth factor
is EGFR-CD533.